GL Stock Forecast & Price Target

Globe Life is supported by a durable franchise serving lower-middle and middle-income U.S. households through an exclusive distribution model that reduces price competition and has historically produced consistent premium growth, solid underwriting, and below-peer balance sheet risk. Its outlook is further strengthened by improving core operations, including 1Q26 underwriting margin of 40.9%, 58% Health sales growth, and expectations for low-double-digit EPS growth driven by mid-single-digit premium growth, higher net investment income, and expense leverage. Capital generation adds another layer of upside, with 2026 buyback guidance raised to $725-$775M, parent cash flow of $650-$700M, and Bermuda-related cash flow and dividend potential expected to become more meaningful beginning in 2027.

Globe Life is facing a more fragile earnings profile as elevated medical claims severity and Medicare Supplement claim irregularities are expected to keep Health results volatile through 4Q and into subsequent periods, with only partial relief from 2Q27 rate increases. The company cut 2026E EPS to $15.49 from $15.75 and 2027E EPS to $16.40 from $16.60, reflecting lower projected Health margins of 21% versus 25%, slightly weaker excess net investment income, and only partially offsetting support from higher Life margins and buybacks. Despite reinsurance and diversification, the stock’s valuation already appears to reflect its current prospects, while persistent downside risk remains from adverse claims selection, lingering processing effects, and a less robust 2027 core earnings trajectory than expected.